Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px
Organisation › Details

Ncardia (BE, HQ)

Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. The company’s goal is to enable biopharmaceutical companies in drug discovery and cell therapy to accelerate their development processes through the integration of human iPSC technologies. Following the formation of a strategic partnership with Kiniciti, including a $60 million investment, Ncardia is globally expanding its drug discovery and cell therapy services by developing more robust offerings, building GMP capabilities and developing allogeneic immune cell manufacturing platforms. *

 

Period Start 2017-09-18 merged
  Group Kiniciti Bio (WCAS invesment platform) (Group)
  Predecessor Axiogenesis AG
Products Industry iPSC technology (induced pluripotent stem cell technology)
  Industry 2 assay, research
Persons Person Braam, Stefan (Ncardia 201709– CEO before Pluriomics)
  Person 2 Bohlen, Heribert (Axiogenesis 201603 CEO)
     
Region Region Gosselies
  Country Belgium
  Street 47 Rue Adrienne Bolland
  City 6041 Gosselies
    Address record changed: 2020-12-02
     
Basic data Employees C: 51 to 100 (2017-09-18)
     
    * Document for �About Section�: Ncardia Services B.V.. (2/24/22). "Press Release: Ncardia Appoints Andy Holt as Chief Commercial Officer". Leiden.
     
   
Record changed: 2022-05-02

Advertisement

Picture [iito] Männer Ballett 650x100px

More documents for Kiniciti Bio (WCAS invesment platform) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top